Feed / OFIX

Orthofix Medical Inc.

OFIX

Healthcare · 8.85 -0.8% today

Isolated · not yet confirmedMarket checked 11 Sept, 12:45 GMT-4

Market read

Orthofix Medical Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.

Company-0.8% todayVolume comparison unavailable
Market group0 of 12 activeResidential REITs & Insurers · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • OFIX's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if OFIX's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • OFIX's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements33
Verified relationships7
Evidence supporting the case
  • Net margin changed +4.5 percentage points in the latest annual period.
  • Demand and volume has repeated favorable evidence across 3 filings.
  • Foreign exchange has repeated favorable evidence across 3 filings.
Evidence challenging the case
  • Diluted shares increased 3.9% in the latest annual period.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

8.69
6m-35.8%12m-41.5%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$464.5M+14.2%$-1.95+1.5%
2022-12-31$460.7M-0.8%$-0.98+1.8%
2023-12-31$746.6M+62.1%$-4.12
2024-12-31$799.5M+7.1%$-3.30+3.8%
2025-12-31$822.3M+2.9%$-2.33+3.9%

What management says matters

Persistent and emerging business drivers

Demand and volumepositive · 3 filings
Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems.
10-Q · May 5, 2026
Foreign exchangepositive · 3 filings
t currency basis, primarily driven by sales of new products launched in the past three years and partially offset by large tender orders in the prior year • Net sales increase of $2.2 million due to movement in foreign currency exchange rates, which had a fav…
10-Q · May 5, 2026
Product pipeline and R&Dmixed · 2 filings
Dollars, in thousands) 2026 2025 % Change Research and development $ 15,320 $ 19,766 (22.5 %) As a percentage of net sales 7.8 % 10.2 % (2.4 %) Three months ended March 31, 2026 compared to 2025 Research and development expense decreased $4.4 million • Decrea…
10-Q · May 5, 2026
Restructuring and cost reductionsmixed · 2 filings
Three months ended March 31, 2026 compared to 2025 Acquisition-related amortization, impairment, and remeasurement decreased $14.0 million • Decrease of $15.4 million in amortization expense primarily associated with the impairment of certain acquired intangi…
10-Q · May 5, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

8.85-0.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for OFIX. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for OFIX. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind OFIX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

HSBCHSBC Holdings plclenderFeb 24, 2026

Credit Agreement On November 7, 2024, the Company entered into a $ 275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including…

JPMJPMorgan Chase & Co.lenderFeb 24, 2026

In November 2023, following the termination of the Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent, and certain lender parties thereto, Bank of America required collateral of approximately $ 4.7 million of…

Depended on by

GMEDGlobus Medical, Inc.competitorFeb 24, 2026

Alphatec Holdings, Orthofix, Integra LifeSciences , ZimVie, Boston Scientific and other smaller public and private companies are also competitors of ours.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

OFIX is currently a Follower in the organic co-movement group Residential REITs & Insurers. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for OFIX; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.